Everest Organics ends 15% higher on development of Molnupiravir, a new API to treat Covid-19

'Molnupiravir' is an API that reduces the risk of hospitalization and death by around 50% for patients with mild or moderate cases of Covid.

Oct 12, 2021 04:10 IST India Infoline News Service

Everest Organics
Everest Organics Limited on Tuesday has announced the successful development of an anti-viral APl 'MOLNUPIRAVIR' an additional COVID -19 treatment drug that is being developed at Lab Scale for the first-line treatment of COVID-19 in adults patients with mild to moderate symptoms.

Dr. Srikakarlapudi Sirisha, Chief Executive Officer, EOL - New Product Development said that "After the successful development and commercialization of various COVID-19 drugs, such as Oseltamivir, Remdesivir, Posaconazole, Everest Organics Limited is on its path of expansion of this portfolio and hence has further developed an additional COVID-19 treatment API in that segment.

'Molnupiravir' is an API that reduces the risk of hospitalization and death by around 50% for patients with mild or moderate cases of Covid.

The APl, Molnupiravir is administered orally and works by inhibiting the replication of the coronavirus inside the body. Everest is planning and preparing to be an active player in viral segment in the upcoming future.

Everest Organics ended at Rs347.10 apiece up by Rs46.85 or 15.6% on Sensex.

Related Story

Open Free Demat Account (Rs699)